Document is current
Any future updates will be listed below
-
Authors
Weinstein, Cindy
Jordan, Karin
Green, Stuart A.
Camacho, Elber
Khanani, Saleem
Beckford-Brathwaite, Elizabeth
Pong, Annpey
Noga, Stephen J.
Rapoport, Bernardo L.
-
Funding
Funding for this research was provided by:
Merck
- License Information
-
More Information
Article History
Received: 1 December 2017
Accepted: 30 April 2018
First Online: 28 May 2018
Compliance with ethical standards
: The trial was conducted in accordance with the Declaration of Helsinki and Good Clinical Practice guidelines. The study protocol was approved by ethics committees at each center (see Online Resource InternalRef removed for the full listing of centers); all patients (or their legal representatives) provided written informed consent before enrollment. This trial is registered at ExternalRef removed, number NCT01594749.
: Dr. Weinstein is an employee of Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Kenilworth, NJ, USA, and is a stockholder in the company. Dr. Jordan received consultant fees from Merck Sharp & Dohme Corp., Helsinn, and Tesaro. Dr. Green is an employee of Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Kenilworth, NJ, USA, and is a stockholder in the company. Dr. Camacho has nothing to disclose. Dr. Khanani has nothing to disclose. Dr. Beckford-Brathwaite is an employee of Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Kenilworth, NJ, USA, and is a stockholder in the company. Dr. Pong is an employee of Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Kenilworth, NJ, USA, and is a stockholder in the company. Dr. Noga is now an employee of Takeda Oncology. Dr. Rapoport acted on advisory boards for Merck & Co., Inc., Tesaro, and Heron Therapeutics, and acted on speakers’ bureaus for Tesaro.
